We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Lung Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Swapan Kumar Nath
Feb 06, 2021
I think immunotherapy (pembrolizumab) plus chemotherapy ( platinum plus pemitrexate) would be the best first choice.
Jean-Yves Douillard
Feb 09, 2021
I would suggest Pembrolizumab + chemotherapy (Platinum Pemetrexed), my main rational for adding chemo here is the presence of liver metastasis that respond poorly to immunotherapy and are a bad prognostic factor
I would also remember the Kras G12D mutation and look for a clinical trial (if any!) with a targeted agent in later line.
Mahmoud Soliman
Apr 11, 2021
pembro + chemo...
Kras g12c eligable for sotorasib not g12d
GALA NAUSICAA ROMERO MORATALLA
Nov 18, 2021
initial chemotherapy ( CDDP with pemetrexed and pembrolizumab)
after that evaluation to Sotorasib for KRAS G12D mutations
Apr 24, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Michael
J.
Grant
MD
Swapan Kumar Nath
Feb 06, 2021
Jean-Yves Douillard
Feb 09, 2021
Mahmoud Soliman
Apr 11, 2021
GALA NAUSICAA ROMERO MORATALLA
Nov 18, 2021
Apr 24, 2024
Pending Moderator approval.